NCT06925321 - A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions

Invasive Mold Infections

Interventions

DRUG

Fosmanogepix IV infusion

Fosmanogepix will be administered IV

DRUG

Standard of care antifungal therapy

Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines

DRUG

Fosmanogepix oral tablet

Fosmanogepix will be administered orally.

Trial Locations (1)

RECRUITING

Washington University School of Medicine, Infectious Diseases Clinical Research Unit, St Louis